Cargando…
Recent Developments in Preclinical DNA Vaccination
The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and th...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494203/ https://www.ncbi.nlm.nih.gov/pubmed/26344468 http://dx.doi.org/10.3390/vaccines2010089 |
_version_ | 1782380043297619968 |
---|---|
author | Okuda, Kenji Wada, Yoshiyuki Shimada, Masaru |
author_facet | Okuda, Kenji Wada, Yoshiyuki Shimada, Masaru |
author_sort | Okuda, Kenji |
collection | PubMed |
description | The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here. |
format | Online Article Text |
id | pubmed-4494203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-44942032015-08-31 Recent Developments in Preclinical DNA Vaccination Okuda, Kenji Wada, Yoshiyuki Shimada, Masaru Vaccines (Basel) Review The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here. MDPI 2014-01-13 /pmc/articles/PMC4494203/ /pubmed/26344468 http://dx.doi.org/10.3390/vaccines2010089 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Okuda, Kenji Wada, Yoshiyuki Shimada, Masaru Recent Developments in Preclinical DNA Vaccination |
title | Recent Developments in Preclinical DNA Vaccination |
title_full | Recent Developments in Preclinical DNA Vaccination |
title_fullStr | Recent Developments in Preclinical DNA Vaccination |
title_full_unstemmed | Recent Developments in Preclinical DNA Vaccination |
title_short | Recent Developments in Preclinical DNA Vaccination |
title_sort | recent developments in preclinical dna vaccination |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494203/ https://www.ncbi.nlm.nih.gov/pubmed/26344468 http://dx.doi.org/10.3390/vaccines2010089 |
work_keys_str_mv | AT okudakenji recentdevelopmentsinpreclinicaldnavaccination AT wadayoshiyuki recentdevelopmentsinpreclinicaldnavaccination AT shimadamasaru recentdevelopmentsinpreclinicaldnavaccination |